Several DPP-IV inhibitors and GLP-1 analogs (with improved plasma half-lives, such as liraglutide and semaglutide) have been developed and proven to be highly successful in the treatment of type 2 diabetes mellitus (T2DM) and obesity [3]. Here, GLP1R is linked to type 2 diabetes mellitus.